Glial cell line-derived neurotrophic factor antibody

• US 5,935,795 A
• Filed: 05/26/1995
• Issued: 08/10/1999
• Est. Priority Date: 09/20/1991
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Collins, Franklin D., Doherty, Daniel H., Lin, Leu-Fen H., Lile, Jack, Bektesh, Susan
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Krikorian, Jacqualine G.
• Application Number:
  US08/452,242
• Time in Patent Office: 1,537 Days
• Field of Search: 530/387.1, 530/388.2, 530/388.24, 530/389.2, 530/387.9, 530/388.23, 530/388.85, 530/399, 530/809, 530/839, 435/70.21, 435/240.27, 435/7.1, 435/7.2, 435/7.21, 436/63, 436/501
• US Class Current: 435/7.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: Y10S 530/809 Fused cells, e.g. hybridoma
• CPC Class Codes: Y10S 530/839 Nerves; brain

Abstract

A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. Antibodies to GDNF are disclosed, as well as methods for identifying members of the GDNF family of neurotrophic factors.

Claims

1. An antibody that binds to glial cell line-derived neurotrophic factor having the amino acid sequence as set forth in SEQ ID NO:

4 or SEQ ID NO;

6.

2. The antibody of claim 1 which is a monoclonal antibody.

3. The antibody of claim 1 which is a polyclonal antibody.

6. A process for detecting glial cell line-derived neurotrophic factor comprising the steps of contacting said factor with an antibody of claim 1 to form an antibody-factor complex, and detecting said complex.

7. The process of claim 6 wherein said antibody is a monoclonal antibody.

8. The process of claim 6 wherein said antibody is a polyclonal antibody.

9. A process for quantitating glial cell line-derived neurotrophic factor comprising the steps of contacting said factor with an antibody of claim 1 to form an antibody-factor complex, detecting said complex, and measuring the amount of said complex present.

10. The process of claim 9 wherein said antibody is a monoclonal antibody.

11. The process of claim 9 wherein said antibody is a polyclonal antibody.

4. An antibody produced by immunizing an animal with glial cell line-derived neurotrophic factor having the amino acid sequence as set forth in SEQ ID NO:

4 or SEQ ID NO;

6.

5. A hybridoma cell line that produces a monoclonal antibody that binds to glial cell line-derived neurotrophic factor having the amino acid sequence as set forth in SEQ ID NO:

4 or SEQ ID NO;

6.